22:49 , Jun 15, 2018 |  BC Extra  |  Preclinical News

ThinkCyte launches with AI-based high-throughput cell sorter

ThinkCyte Inc. (Tokyo, Japan) launched to develop an artificial intelligence-enabled, image-free visual cell sorting system that can sort cells by morphology at higher speeds and with greater accuracy than current methods. The company believes its...
21:18 , Dec 6, 2017 |  BC Innovations  |  Emerging Company Profile

Building up nerve

AxoSim Technologies LLC has developed a 3-D human nerve-on-a-chip platform to recapitulate the in vivo organization of nerve bundles with greater fidelity to human systems than competitor models. The service provider is positioning its system...
07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...
07:00 , Apr 28, 2016 |  BC Innovations  |  Finance

Bridging translation

An increasing number of academic institutions are filling the translational gap between what typical academic projects produce and what companies or VC firms want to see in order to commercialize a discovery. These organizations, or...
07:00 , Apr 20, 2009 |  BioCentury  |  Finance

Ebb & Flow

Investors scrambled last Tuesday to cover the 20% of Dendreon Corp. shares that they had sold short, after the company unveiled a positive topline survival result from the Phase III IMPACT trial of its prostate...
00:12 , Sep 29, 2007 |  BC Extra  |  Politics & Policy

House passes SBIEA bill

The House of Representatives on Thursday passed the Small Business Investment Expansion Act (H.R. 3567) in a 325-72 vote. The bill, which is sponsored by Rep. Jason Altmire (D-Penn.), would allow small businesses that accept...
08:00 , Feb 10, 1997 |  BioCentury  |  Finance

Blech resurfaces

Following more than two years of relative invisibility, investor David Blech has resurfaced, making $5.8 million in open market purchases in GeneMedicine (GMED) over the last two months. The 30 transactions, totaling 907,000 shares, could...